Shire PLC (LON:SHP) had its target price lowered by Morgan Stanley from GBX 5,800 ($76.26) to GBX 5,700 ($74.94) in a report published on Thursday morning. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the company. Shore Capital restated a buy rating on shares of Shire PLC in a research report on Wednesday, June 21st. HSBC Holdings plc upgraded Shire PLC to a hold rating and set a GBX 4,450 ($58.51) price target for the company in a research report on Thursday, July 6th. Royal Bank Of Canada reiterated an outperform rating on shares of Shire PLC in a research report on Friday, July 7th. J P Morgan Chase & Co reiterated an overweight rating and set a GBX 6,000 ($78.89) price target on shares of Shire PLC in a research report on Tuesday, July 11th. Finally, Liberum Capital reiterated a hold rating and set a GBX 4,900 ($64.42) price target on shares of Shire PLC in a research report on Wednesday, June 21st. Four investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of GBX 5,829.67 ($76.65).
Shares of Shire PLC (SHP) opened at 3848.00 on Thursday. Shire PLC has a one year low of GBX 3,603.50 and a one year high of GBX 5,186.00. The firm’s market capitalization is GBX 34.88 billion. The company’s 50 day moving average price is GBX 3,870.83 and its 200 day moving average price is GBX 4,251.02.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/15/morgan-stanley-trims-shire-plc-shp-target-price-to-gbx-5700.html.
The company also recently disclosed a dividend, which will be paid on Friday, October 20th. Stockholders of record on Thursday, September 7th will be paid a GBX 3.85 ($0.05) dividend. This represents a dividend yield of 0.1%. The ex-dividend date of this dividend is Thursday, September 7th.
In related news, insider Anne Minto bought 190 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were bought at an average cost of GBX 3,785 ($49.76) per share, with a total value of £7,191.50 ($9,455.04). Also, insider Flemming Ornskov bought 8,400 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average cost of GBX 3,665 ($48.19) per share, for a total transaction of £307,860 ($404,759.40).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.